Reply to: “Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation”  by Coilly, Audrey et al.
[4] Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complica-
tions of the graft in interferon-treated hepatitis C positive liver transplant
recipients. J Hepatol 2011;55:207–217.
[5] Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, et al. Risk for
immune-mediated graft dysfunction in liver transplant recipients with
recurrent HCV infection treated with pegylated interferon. Gastroenterology
2012;142:1132–1139.
[6] Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, et al. Hepatitis
C virus therapy, hepatocyte drug metabolism, and risk for acute cellular





Department of Surgery and Science,
Graduate School of Medical Science,
Kyushu University, 3-1-1, Higashi-ku,
Fukuoka 812-8582, Japan⇑Corresponding author.
E-mail address: tikesurg@surg2.med.kyushu-u.ac.jp
Reply to: ‘‘Frequent plasma cell hepatitis during telaprevir-based
triple therapy for hepatitis C after liver transplantation’’
To the Editor:
We much appreciate Dr Ikegami and colleagues’ comments on
our study on the use of a ﬁrst generation protease inhibitor-based
regimen to treat hepatitis C (HCV) recurrence after liver
transplantation (LT) [1]. One comment concerned the lack of
occurrence of plasma cell hepatitis (PHC) in our series of 37
patients. Dr Ikegami reported on 9 patients treated with telapre-
vir (TVR), peginterferon a2b (PegIFN) and ribavirin (RBV) in a
context of HCV recurrence after living donor LT. PHC occurred
in 33.3% of patients (3/9) during triple therapy, compared with
6.7% (7/105) during standard PegIFN/RBV. We have developed
some arguments to explain the difference between these two
different ﬁndings.
A low immunosuppressive regimen is a risk factor for the
development of PCH [2]. All patients in Dr Ikegami’s letter
received cyclosporine (CsA) ± mycophenolate mofetil (MMF).
Data concerning targeted trough blood concentrations (TBC) of
CsA, and the delay between triple therapy and LT, were lacking.
All PHC cases reported by Dr Ikegami occurred after the discon-
tinuation of TVR (weeks 21, 31, and 12). Despite biweekly moni-
toring, the mean CsA TBC in patient 3 was low after week 12
(from 53 to 86 ng/ml). Drug-drug interactions between PI and
calcineurin inhibitors have always been the main challenge when
using PI after LT. In the ﬁrst instance, we focused on the PI initi-
ation period to demonstrate its feasibility in terms of practical
management [3]. We also looked carefully at the time of PI dis-
continuation. In our study, TBC were monitored daily and CsA
doses were also adjusted daily to reach the target range. It was
necessary to increase the CsA doses by 47% after TVR discontinu-
ation [1]. In this context, HCV clearance might have an impact on
PHC occurrence with triple therapy, but drug-drug interactions
are more likely to be responsible for the excess risk found by Ike-
gami et al.
One observation in Dr Ikegami’s letter was particularly sur-
prising, and concerned the favorable outcome of PHC in all
patients. This contrasted with the usually poor prognosis of
PHC in a context of HCV recurrence. According to Fiel et al.,
patients who were not treated or were receiving corticosteroids
had a negative outcome. Cirrhosis was seen to develop in 60%
of patients (4). According to Dr Ikegami, patients 1 and 2 were
treated with steroid pulses and an increase in or addition of
mycophenolate mofetil (MMF). For patient 1, we could hypothe-
size that acute cellular rejection (ACR) justiﬁed such a treatment.
And as for patient 3, MMF and low-dose corticosteroids (5 mg)
were added to CsA.
The prevalence of PHC may vary, depending on the diagnosis
criteria applied. Most studies on PHC have considered that this
diagnosis is based on three criteria: (1) abnormality of liver tests,
(2) increased levels of immunoglobulin G and/or speciﬁc anti-
bodies of auto-immune hepatitis, (3) compatible histological fea-
tures. Dr Ikegami does not mention any serological data.
Furthermore, we have some concerns about the histological ﬁnd-
ings. The authors considered that the diagnosis was based on the
presence of centrilobular and portal necrosis and a prominent
(>30%) plasma cell (PC) aggregation, as previously described by
Fiel et al. [4]. In patient 1, PHC was associated with ACR. The dif-
ferential diagnosis between these entities can be difﬁcult. In
severe ACR, a severe portal necro-inﬂammatory activity may
mimic hepatitis. The inﬁltrate may be made up of PC, but with-
out proper PCH. In order to clarify the histological features of
PCH, we recently reported on a scoring system based on centrilob-
ular changes such as necro-inﬂammatory activity (NIA) and the
centrilobular PC ratio. The positive predictive value of the associ-
ation of severe centrilobular NIA and a PC ratio of up to 30% was
>90% [5]. In fact, we currently use these criteria to diagnose PCH.
To conclude, we agree with Dr Ikegami that PCH is a potential
complication of a TVR-based antiviral regimen. For as long as an
interferon-based regimen is used after LT, hepatologists should
be alert to possibilities of PHC occurrence. Close monitoring of
drug-drug interactions is warranted, particularly soon after PI
initiation and also at the time of PI discontinuation. We also think
that using stringent criteria based on serological markers and
histological features is crucial to preventing a misdiagnosis of
PHC.
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DHEA and progesterone have a protective effect
on ribavirin-induced hemolysis
To the Editor:
We read with great interest the recent article by Scherzer et al.
who investigated the relationship between ITPA polymorphism
and decreased hemoglobin levels in 308 Austrian patients [1].
In their cohort, they conﬁrmed the protective effect of ITPA poly-
morphisms on ribavirin-induced anemia. However, surprisingly,
premenopausal females in their population were less likely
develop ribavirin-induced anemia irrespective of the protective
effect of ITPA mutations. In multivariate analysis of a >3 g/dl
decrease in hemoglobin, menopause was the most signiﬁcant
variable (OR = 2.814, 95% CI 1.027–7.714, p = 0.044). A similar
result was not observed when comparing men less than 50 and
older than 50. Scherzer et al. tried to advance explanations for
these differences between premenopausal and postmenopausal
women related to the protective effect of female hormones.
We have recently developed a new in vitro tool for analysis of
ribavirin-induced red blood cell lysis based on the ribavirin concen-
tration [2]. This test can be used to study molecules able to inhibit
ribavirin-induced hemolysis. We therefore used this test to evalu-
ate molecules associated with a physiological decrease in plasma
concentrations between premenopausal and postmenopausal
women. We tested the following molecules in the presence of
2 mM ribavirin: b-estradiol, estradiol, estrone, progesterone,
androstenedione, and DHEA. Under our experimental conditions,
in the presence of 2 mM ribavirin (intraerythrocytic ribavirin con-
centration in treated patients [3]), a hemolysis rate of about 20%
was obtained. The percentage hemolysis for this condition was
set to 100%. Interestingly, progesterone and DHEA strongly and
dose-dependently attenuated ribavirin-induced hemolysis
(Fig. 1). The various experimental conditions were repeated 6
times. For example, by adding DHEA at concentrations of
0.01 mg/ml and 0.02 mg/ml to the ribavirin medium, hemolysis
was decreased by 31.87% (±2.9%, p <0.001) and 63.93% (±0.96%,
p <0.001), respectively. Addition of progesterone at a concentration
of 100 lM decreased hemolysis by 39.17% (±2.75%, p <0.001). On
the basis of our preliminary results, we also tested structural ana-
logs of progesterone (mifepristone, levonorgestrel, and predni-
sone), which also demonstrated protection towards ribavirin-
induced hemolysis but to a lesser extent (data not shown).
Plasma DHEA levels decrease progressively with age in both
men and women with a marked disparity of concentrations
observed in the same age-group [4]. Plasma DHEA levels are in
the range 600 to 3400 ng/ml in women between the ages of 25
and 44 years, and in the range 120 to 2500 ng/ml in women
between the ages of 45 and 75 years. The results presented in
Fig. 1 show that a small variation in the DHEA concentration
(from 0.01 mg/ml to 0.02 mg/ml) leads to a signiﬁcant reduction
of ribavirin-induced hemolysis. Circulating progesterone levels
fall to below 1 ng/ml in postmenopausal women.
These results may provide an explanation for the data
obtained by Scherzer et al. [1]. However, the way in which
these molecules counteract the adverse effects of ribavirin on
red blood cells remain unknown. It is commonly accepted that
ribavirin-induced hemolysis is the result of a marked decrease
in ATP levels in red blood cells, increasing susceptibility to
oxidation [5]. However, only limited evidence is available
concerning how ribavirin disrupts ATP homeostasis in red
blood cells. Several hypotheses can be proposed, such as con-
sumption of ATP for ribavirin phosphorylation of derivatized
triphosphate. Another explanation could be enzyme inhibition
of the salvage pathway of purine nucleotide synthesis in red
blood cells. The protective effect of DHEA and progesterone
on ribavirin-induced hemolysis could possibly be involved in
the regulation of red blood cell ATP metabolism. The addition
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